Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects
Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate increasing dose levels of VS-4718 administered in
combination with gemcitabine and nab-paclitaxel in subjects with advanced cancer and to
determine a recommended Phase 2 dose (RP2D) for further development of this combination in
subjects with untreated advanced pancreatic cancer.